Loading the company…
Loading the company…
㈜한국바이오팜
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-10-11 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Chungbuk, founded in 2013. Industry: Food & Consumer Goods. Revenue for 2025 was ₩12.7bn. It has 33 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2023-05-03 · latest registration 2026-04-13 · newest first
본 발명은 커큐민, 퀘르세틴, 비타민 D 및 홍삼 추출물을 포함하여, 면역력 증진 및 탈모 방지에 탁월한 효과가 있는 건강기능식품 조성물에 대하여 개시한다. 본 발명에 따른 건강기능식품 조성물은 커큐민 100중량부에 대하여, 퀘르세틴 20 ~ 70중량부; 비타민 D 10 ~ 20중량부; 및 홍삼 추출물 1 ~ 10중량부;를 포함하는 것을 특징으로 한다.
본 발명은 항염 효과가 우수하여, 다양한 염증성 질환을 효과적으로 예방, 개선 또는 치료할 수 있는 조성물에 관한 것이다. 상세하게, 본 발명의 화합물은 염증성 매개 물질인 일산화질소(NO)의 생성을 억제하고, 다양한 염증성 사이토카인인 인터루킨-6(IL-6), TNF-α 및 인터페론-감마(IFN-gamma)의 발현 또한 억제하여 염증성 질환을 효과적으로 예방, 개선 또는 치료할 수 있으며, 인체에 투여하여도 부작용이 없고 안전하다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 2 of 2 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 10.6 | 12.7 |
| Cost of sales | 8.8 | 10.9 |
| Gross profit (loss) | 1.8 | 1.8 |
| Selling, general and administrative expenses | 1.5 | 2.2 |
| Operating income (loss) | 0.3 | (0.4) |
| Non-operating income | 0.1 | 0.1 |
| Other gains | 0.0 | 0.1 |
| Finance income | 0.0 | 0.0 |
| Non-operating expenses | 0.5 | 0.3 |
| Other losses | 0.1 | 0.0 |
| Finance costs | 0.4 | 0.3 |
| Profit (loss) before tax | (0.1) | (0.7) |
| Income tax expense | (0.1) | (0.3) |
| Net income (loss) | 0.0 | (0.3) |
Revenue ₩12.7bn, up 20.2% YoY.
Operating margin -3.2% (prior 3.0%).
Net income ₩-0.3bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.